Cimeio Therapeutics

The company develops a cell-shielding technology platform designed to improve hematopoietic stem cell transplants and adoptive cell therapies for patients with hematologic disorders. Their approach uses gene editing to insert protein variants into healthy cells, protecting them from depletion by paired immunotherapies like ADCs and CAR-T cells while maintaining normal cellular function. This allows for the selective eradication of diseased cells while preserving a patient's healthy immune system.